How I treat high-risk multiple myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Trials

Background:

• Multiple myeloma (MM) survival has improved, but high-risk (HR) MM patients (15-20%) still have reduced survival.
• Tumor biology and treatment response influence HR MM, necessitating clear risk factor identification for effective management.
• Current MM treatment primarily considers age and frailty, with less emphasis on disease biology.

Purpose of the Study:

• To review current definitions of high-risk multiple myeloma (HR MM) and the need for consensus.
• To analyze results from clinical trials involving HR MM patients.
• To explore risk-adapted treatment strategies for difficult-to-treat MM cases.

Main Methods:

• Literature review of current HR MM definitions and clinical trial data.
• Analysis of treatment outcomes in HR MM patients.
• Case study approach to illustrate risk-adapted strategies.

Main Results:

• Minimal residual disease (MRD) negativity is a primary goal in biologic HR MM.
• Treatment adaptation for frail patients can reduce toxicity and improve quality of life.
• Lack of consensus on HR definition and limited prospective trial data hinder biology-driven treatment.

Conclusions:

• A consensus on HR MM definition is crucial for standardized patient management.
• Risk-adapted treatment strategies, considering both disease biology and patient factors, are essential for improving outcomes in HR MM.
• Further prospective clinical trials are needed to validate novel treatment approaches for HR MM.